 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
RPCI-RP-9815
NCI-V99-1527, NCT00003816, RP 98-15
|
|
| |
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
|
|
|
|
Phase III, Phase II
|
|
|
|
UARK 2003-26
NCT00090493
|
|
| |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
|
|
|
|
Phase III, Phase II
|
|
|
|
RPCI-I-72806
I 72806, NCT00536601
|
|
| |
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
|
|
|
Phase III, Phase II
|
|
|
|
0705-20 IUCRO-0196
NCT00594308
|
|
| |
Total-Body Irradiation With Or Without Fludarabine Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
|
|
|
Phase III
|
|
|
|
FHCRC-1813.00
5666, NCT00075478
|
|
| |
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II or Stage III Multiple Myeloma
|
|
|
|
Phase III
|
|
|
|
FHCRC-2004.00
6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
|
|
| |
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
|
|
|
|
Phase III
|
|
|
|
CA200-004
KAG-301, NCT00546780
|
|
| |
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
|
|
|
|
Phase III
|
|
|
|
2006-05
NCT00573391
|
|
| |
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
|
|
|
|
Phase III
|
|
|
|
2006-15
NCT00574080
|
|
| |
Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment
|
|
|
|
Phase III
|
|
|
|
25009
59306670 7R01CA115399, NCT00670631
|
|
